Pricing Log in Create free account

Fulcrum Therapeutics, Inc. (FULC) vs Surrozen, Inc. (SRZN)

Fulcrum Therapeutics, Inc. and Surrozen, Inc. are both Biotechnology companies. Fulcrum Therapeutics, Inc. and Surrozen, Inc. are of similar size ($294.7M and $280.0M). Fulcrum Therapeutics, Inc. grew revenue faster over the last twelve months: 1,939.8% against −8.79%. Fulcrum Therapeutics, Inc. has the higher net margin (0.00% vs −2,887.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Fulcrum Therapeutics, Inc. leads on 9 and Surrozen, Inc. on 4.

Valuation

Metric FULC SRZN Biotechnology median
P/E n/m n/m 8.50
P/S 3.37 23.78 9.71
P/B 0.90 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.43 n/m 0.64
EV/Sales (0.49) 14.92 9.21
Earnings yield (33.15%) (159.31%) (33.15%)
Free cash flow yield (23.60%) (12.78%) (25.50%)

Profitability

Metric FULC SRZN Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% (385.28%) 0.00%
Net margin 0.00% (2,887.07%) 0.00%
Free cash flow margin 0.00% (303.92%) 0.00%
Return on equity (32.38%) 387.44% (56.36%)
Return on assets (30.75%) (304.47%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric FULC SRZN Biotechnology median
Revenue growth (TTM) 1,939.80% (8.79%) 6.02%
EPS growth (last fiscal year) (637.50%) (49.38%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric FULC SRZN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 31.35 12.14 4.72
Net debt to EBITDA 4.23 2.15 0.96

Dividend

Metric FULC SRZN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric FULC SRZN Biotechnology median
Market cap 280.01m 294.66m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack